FindTrial
Sign In

SNG001

DRUG5 trials

Sponsors

Synairgen Research Limited, Synairgen Research Ltd., National Institute of Allergy and Infectious Diseases (NIAID)

Conditions

COVID-19CoronavirusCovid19Lower respiratory tract viral infectionsSARS-CoV-2Severe Acute Respiratory Syndrome Coronavirus 2Viral Pneumonia

Phase 2

Trial of Inhaled Anti-viral (SNG001) for SARS-CoV-2 (COVID-19) Infection
CompletedNCT04385095
Synairgen Research Ltd.SARS-CoV-2
Start: 2020-03-16End: 2021-11-16Updated: 2023-01-04
ACTIV-2: A Study for Outpatients With COVID-19
CompletedNCT04518410
National Institute of Allergy and Infectious Diseases (NIAID)Coronavirus, Covid19
Start: 2020-08-19End: 2023-06-20Updated: 2024-08-02
Phase 2 Study of Inhaled SNG001 in Mechanically Ventilated Patients With Respiratory Viral Infection
RecruitingNCT06999603
Synairgen Research Ltd.Viral Pneumonia
Start: 2025-09-02End: 2027-05-31Target: 550Updated: 2025-12-31
A phase 2, two-part study to assess the safety, antiviral biomarker responses, and efficacy of inhaled SNG001 for the treatment of patients with a confirmed respiratory virus infection undergoing invasive mechanical ventilation
Not yet recruitingCTIS2024-520375-27-00
Synairgen Research LimitedLower respiratory tract viral infections
Target: 134Updated: 2026-01-13

Phase 3

Study to Assess Efficacy and Safety of Inhaled Interferon-β Therapy for COVID-19
CompletedNCT04732949
Synairgen Research Ltd.COVID-19, Severe Acute Respiratory Syndrome Coronavirus 2
Start: 2021-01-12End: 2022-02-10Updated: 2023-03-27

Related Papers

Association Between Anterior Nasal and Plasma SARS-CoV-2 RNA Levels and Hospitalization or Death in Nonhospitalized Adults With Mild-to-Moderate COVID-19
UNC Libraries2025-02-05
Symptom and Viral Rebound in Untreated SARS-CoV-2 Infection
UNC Libraries2025-02-05
One Week of Oral Camostat Versus Placebo in Nonhospitalized Adults With Mild-to-Moderate Coronavirus Disease 2019: A Randomized Controlled Phase 2 Trial
UNC Libraries2025-02-05
Validity and Characterization of Time to Symptom Resolution Outcome Measures in the ACTIV-2/A5401 Outpatient COVID-19 Treatment Trial
UNC Libraries2025-02-05
Statistical Challenges When Analyzing SARS-CoV-2 RNA Measurements Below the Assay Limit of Quantification in COVID-19 Clinical Trials
UNC Libraries2025-02-05
Safety and Efficacy of Combination SARS-CoV-2 Neutralizing Monoclonal Antibodies Amubarvimab Plus Romlusevimab in Nonhospitalized Patients With COVID-19
UNC Libraries2025-02-05
Impact of SARS-CoV-2 Resistance to Antiviral Monoclonal Antibody Therapy on Neutralizing Antibody Response
UNC Libraries2024-10-03
Variant-Specific Viral Kinetics in Acute COVID-19
UNC Libraries2024-09-01
Pooling Different Placebos as a Control Group in a Randomized Platform Trial: Benefits and Challenges From Experience in the ACTIV-2 COVID-19 Trial
UNC Libraries2024-09-01
Immune Status and SARS-CoV-2 Viral Dynamics
UNC Libraries2024-09-01
Long COVID After Bamlanivimab Treatment
UNC Libraries2024-09-01
Impact of SARS-CoV-2 Resistance to Antiviral Monoclonal Antibody Therapy on Neutralizing Antibody Response
Pathogens and Immunity2024-08-212 citations
Safety and Efficacy of SAB-185 for Nonhospitalized Adults With COVID-19: A Randomized Clinical Trial
The Journal of Infectious Diseases2024-07-181 citations
SARS-CoV-2 Plasma Antibody and Nucleocapsid Antigen Status Predict Outcomes in Outpatients With COVID-19
Clinical Infectious Diseases2024-07-172 citations
Nasal and Plasma Severe Acute Respiratory Syndrome Coronavirus 2 RNA Levels Are Associated With Timing of Symptom Resolution in the ACTIV-2 Trial of Nonhospitalized Adults With Coronavirus Disease 2019
UNC Libraries2023-10-11
Safety and efficacy of inhaled interferon-β1a (SNG001) in adults with mild-to-moderate COVID-19: a randomized, controlled, phase II trial.
2023-10-069 citations
One Week of Oral Camostat Versus Placebo in Nonhospitalized Adults With Mild-to-Moderate Coronavirus Disease 2019: A Randomized Controlled Phase 2 Trial.
2023-10-0114 citations
ACTIV-2: A Platform Trial for the Evaluation of Novel Therapeutics for the Treatment of Early COVID-19 in Outpatients
The Journal of Infectious Diseases2023-08-3112 citations
Immune Status and SARS-CoV-2 Viral Dynamics
The Journal of Infectious Diseases2023-08-3112 citations
Pooling Different Placebos as a Control Group in a Randomized Platform Trial: Benefits and Challenges From Experience in the ACTIV-2 COVID-19 Trial
The Journal of Infectious Diseases2023-08-318 citations

20 more papers not shown